BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15382076)

  • 1. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
    Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ
    Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
    Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ
    Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
    Matheson SL; McNamee J; Jean-Claude BJ
    J Pharmacol Exp Ther; 2001 Mar; 296(3):832-40. PubMed ID: 11181914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
    Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.
    Huang Y; Rachid Z; Peyrard L; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
    Chem Biol Drug Des; 2015 Feb; 85(2):153-62. PubMed ID: 25092264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
    Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
    Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
    Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
    Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
    Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
    Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
    Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.